December 21, 2016
FDA accepts Vernalis and Tris Pharma’s NDA for cough drug
U.S. Food and Drug Administration (“FDA”) has accepted Vernalis and Tris Pharma’s CCP-08 New Drug Application (“NDA”) for full review.…
Pharmaceuticals, Biotechnology and Life Sciences
U.S. Food and Drug Administration (“FDA”) has accepted Vernalis and Tris Pharma’s CCP-08 New Drug Application (“NDA”) for full review.…
Vernalis has today announced the completion of the CCP-08 pivotal multiple-dose comparative bioavailability study.
Vernalis plc has announces that it has acquired the US rights to Moxatag (amoxicillin extended-release tablets) from Pragma Pharmaceuticals, LLC (“Pragma”).